EICHOR
● Completed
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Condition: Chorea, Huntington · Sponsor: Neurocrine Biosciences
About this study
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (34)
| Neurocrine Clinical Site | Birmingham, Alabama, United States | — |
| Neurocrine Clinical Site | Little Rock, Arkansas, United States | — |
| Neurocrine Clinical Site | La Jolla, California, United States | — |
| Neurocrine Clinical Site | Aurora, Colorado, United States | — |
| Neurocrine Clinical Site | Washington D.C., District of Columbia, United States | — |
| Neurocrine Clinical Site | Boca Raton, Florida, United States | — |
| Neurocrine Clinical Site | Gainesville, Florida, United States | — |
| Neurocrine Clinical Site | Atlanta, Georgia, United States | — |
| Neurocrine Clinical Site | Chicago, Illinois, United States | — |
| Neurocrine Clinical Site | Chicago, Illinois, United States | — |
| Neurocrine Clinical Site | Indianapolis, Indiana, United States | — |
| Neurocrine Clinical Site | Iowa City, Iowa, United States | — |
+ 22 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04400331